216 related articles for article (PubMed ID: 36267742)
1. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
Xue Y; Ren Y; Yan B; Li Z; Huang C
Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
4. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
5. Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.
Zhang H; Cong X; Yin J; Chen C; Liu Z
Front Oncol; 2024; 14():1387388. PubMed ID: 38715777
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
7. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
8. Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic
Huang Y; Zhang S; Hu X; Wang X; Zhao Y; Li Z
AME Case Rep; 2024; 8():38. PubMed ID: 38711893
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
10. Treatment of
Gowda S; Sandow L; Heinrich MC
J Gastrointest Oncol; 2024 Apr; 15(2):788-793. PubMed ID: 38756640
[TBL] [Abstract][Full Text] [Related]
11. Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With
Niu X; Sun Y; Planchard D; Chiu L; Bai J; Ai X; Lu S
Front Oncol; 2021; 11():634920. PubMed ID: 34178624
[TBL] [Abstract][Full Text] [Related]
12. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
14. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
Tan X; Wu Z; Chen M
Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
[TBL] [Abstract][Full Text] [Related]
15. Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.
Li SD; Martial A; Schrock AB; Liu JJ
Exp Hematol Oncol; 2017; 6():29. PubMed ID: 29142786
[TBL] [Abstract][Full Text] [Related]
16. Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
Ota T; Okabayashi A; Fukuoka M
Respirol Case Rep; 2021 Oct; 9(10):e0841. PubMed ID: 34484797
[TBL] [Abstract][Full Text] [Related]
17. Targeting BRAF mutations in non-small cell lung cancer.
O'Leary CG; Andelkovic V; Ladwa R; Pavlakis N; Zhou C; Hirsch F; Richard D; O'Byrne K
Transl Lung Cancer Res; 2019 Dec; 8(6):1119-1124. PubMed ID: 32010589
[TBL] [Abstract][Full Text] [Related]
18. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of non-small cell lung cancer patients with non-V600E
Lazar R; Fischbach C; Schott R; Somme L
Front Oncol; 2024; 14():1307882. PubMed ID: 38601760
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in
Hirai N; Hatanaka Y; Hatanaka KC; Uno Y; Chiba SI; Umekage Y; Minami Y; Okumura S; Ohsaki Y; Sasaki T
Transl Lung Cancer Res; 2021 Sep; 10(9):3737-3744. PubMed ID: 34733624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
